Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Two-Drug combo beat standard care for BPH?

NCT ID NCT06944145

Disease control Sponsor: Beth Israel Deaconess Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding raloxifene to the standard drug finasteride works better than finasteride alone for men with an enlarged prostate (BPH). About 242 adults will take either the combo or finasteride plus a placebo for 12 months. The goal is to see if the combo improves urinary symptoms more than the single drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
finasteride and raloxifene
What this could lead to
If successful, this combination could offer a more effective treatment option for men with BPH who don't respond to finasteride alone.
What could go wrong
This is a mid-stage trial with 242 participants, so results may not apply to everyone. Adding raloxifene also carries risks like blood clots, which are already listed as an exclusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 242 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria 1. ≥18 yrs old on the day of study consent; 2. Finasteride has been recommended for treatment of BPH by a physician; 3. PSA \<20ng/ml within the last six months; 4. Willingness to maintain any current genitourinary medications (e.g., beta agonists, alpha blockers, anticholinergics); 5. Patient is able and willing to provide written informed consent. Exclusion criteria 1. Active or past history of venous thromboembolism, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis; 2. Previous diagnosis with any prostatic malignancy or precancerous lesions (atypical glandular foci); 3. History of pelvic radiation; 4. Actively receiving intravesical therapy for bladder cancer; 5. Received treatment with any demethylating medications (azacitidine, decitabine, zebularine, guadecitabine, hydralazine); 6. Current use of warfarin; 7. Prior treatment with 5ARI medications (e.g., Finasteride or Dutasteride) in the last year; 8. Diagnosed with diabetes mellitus; 9. Diagnosed with any neurodegenerative diseases; 10. History of allergic reaction to any intravenous (IV) iron replacement products; 11. Currently taking cholestyramine medication; 12. Contraindications to MRI examination, which may include: * Cardiac pacemaker * Intracranial clips, metal implants, or external clips within 10mm of the head * Previous metal injury in the eye or occupation risk to ferrous metal in the eye (e.g. metalworker) * Claustrophobia that cannot be managed with benzodiazepine

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BPH (benign prostatic hyperplasia) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

benign prostatic hyperplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BPH (benign prostatic hyperplasia) Lower urinary track symptoms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    RECRUITING

    Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.